WHAT DOES NEW ADVANCEMENTS IN BRD4 INHIBITION THERAPY ABBV-744 MEAN?

In Segment A, participants will get unique doses and schedules of oral ABBV-744 tablet to determine Harmless dosing routine. Further participants will be enrolled within the recognized monotherapy dosign regimen. In Phase B, members will acquire oral ruxolitinib and ABBV-744 will be given as "insert-on" therapy. In Section C, participants will get